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Abstract
Levodopa-induced dyskinesias are one of the most common disabling motor 
complications in advanced Parkinson’s disease. The subjective perception of motor 
impairment is a clinical phenomenon that needs to be adequately analyzed. Indeed, 
the determination of patient dyskinesias-reduced-self-awareness (DRSA) and of its 
relationship to daily dysfunction is an important aspect of the debate on the gold 
standard for treatment. As the association with executive dysfunction is a matter 
of debate and we hypothesize it plays an important role in DRSA, we analyzed 
metacognitive abilities related to action monitoring and other factors, such as 
response-inhibition and “Theory of Mind,” which represent a novel explanation 
of the phenomenon. Moreover, we investigated whether and how a dysfunction 
in action monitoring related to the cingulo-frontal-ventral striatal circuit would 
be associated with DRSA using an event-related Go-NoGo fMRI experiment. Our 
findings suggest the presence of executive dysfunctions in DRSA pathogenesis, with 
a key leading role played by the cingulo-frontal network as part of a functionally 
impaired response-inhibition network.
Keywords: dyskinesias, self-awareness, action monitoring, theory of mind,  
response-inhibition, fMRI, anterior cingulate cortex
1. Introduction
Parkinson’s disease (PD) is a neurodegenerative disease with a slow but progres-
sive evolution, which mainly involves the control of movements and balance. PD is 
part of a group of diseases called “movement disorders,” and among these, it is the 
most frequent. The disease is present throughout the world and in all ethnic groups. 
It is found in both sexes, with a slight prevalence, perhaps, in males. The average 
age of onset is around 58–60 years, but about 5% of patients may present a juvenile 
onset between 21 and 40 years. Before the age of 20, it is extremely rare. Over the 
age of 60, it affects 1–2% of the population, while the percentage rises to 3–5% 
when the age is above 85.
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The symptoms have perhaps been known for thousands of years: a first descrip-
tion would have been found in an Indian medicine treaty, which referred to a period 
of around 5000 BC. A more recent Chinese document dating back 2500 years is 
also known: “Huangdi Neijing” by Ti Huang [1]. However, the history of the disease 
is linked to the name of James Parkinson, a nineteenth-century London surgeon 
pharmacist, who first described most of the symptoms of the disease in a famous 
booklet, the “An Essay on the Shaking Palsy.”
PD is characterized by cardinal motor symptoms and several non-motor 
features. The former include bradykinesia, rigidity, and tremor, while the latter 
encompass autonomic symptoms, sleep disturbances, and neuropsychological 
disorders (i.e., cognitive impairment and dementia, affective disorders, impulse 
control disorder, psychosis) (see Table 1). In recent years, it has been understood 
that mild cognitive impairment associated with Parkinson’s disease (PD-MCI) 
is more widespread than previously thought. It is estimated that 15–53% of total 
patients suffer from PD-MCI, with a higher frequency among the elderly and 
those with advanced Parkinson’s disease. In 2012, the Movement Disorders Society 
commissioned a taskforce to unify the diagnostic criteria for PD-MCI. PD-MCI 
can be classified into single-domain and multiple-domain subtypes, each of which 
may show impairment in amnestic or non-amnestic domain [2]. Indeed, cogni-
tive deficits associated with PD-MCI tend to involve frontal-based dysfunctions, 
including executive and attention/working memory deficits [3, 4]. Importantly, 
PD-MCI patients are at an increased risk of developing dementia (PDD), compared 
with cognitively intact PD subjects [5]. Neuropsychiatric symptoms such as apathy, 
visual hallucinations, and rapid eye movement sleep behavior disorders are often 
present. Attention processes, executive, recognition memory, and visuospatial 
dysfunctions tend to dominate [6]. In clinical practice, it is important that PDD 
should be recognized and appropriately treated [7].
After a first phase of the disease characterized by a good control of motor 
symptoms with the dopaminergic drugs (mainly levodopa and dopamine-agonists), 
patients inevitably enter the “advanced phase” of PD, developing the so-called 
motor complications, characterized by presence of involuntary movements (dys-
kinesia), painful dystonia, and re-emergence of parkinsonian symptoms (“off” 
periods) that can appear before the next levodopa dose (wearing-off) or suddenly 
(sudden or unpredictable “off”) (see Table 1). In the majority of cases, these com-
plications occur alternately during the same day. Moreover, two opposite issues can 
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• Loss of answer to 
levodopa
• Suboptimal response






• Peak dose dyskinesia
• Diphasic dyskinesia
• “Off” state dystonia
• “On” state dystonia
• Yo-yoing
• Autonomic disorders (gastrointestinal, 
orthostatic hypotension, sweating, 
urologic, sexual dysfunction)
• Sleep disorders (insomnia and sleep 
fragmentation, excessive daytime sleepi-
ness, restless legs syndrome, rapid eye 
movement behavior disorder)
• Sensory disorders
• Mood disorders (depression, anxiety)
• Psychosis
• Cognitive impairment and dementia
Table 1. 
Motor and non-motor complications and classification of levodopa-induced dyskinesias in advanced 
Parkinson’s disease.
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limit the adherence of patients to medical therapies in advanced PD phase. While 
for some patients, the need of dividing the levodopa daily dose in 5 or 6 administra-
tions per day is considered a limitation, other patients develop a sort of craving 
for dopaminergic drugs, partly due to an impulse control disorder, and partly to a 
reduced awareness of therapy complications such as dyskinesia [8, 9].
The subjective experience of what it is like to be a PD patient is fundamental 
for the treatment complaint that is put at risk in cases of poor awareness of symp-
toms. Indeed, PD may result in reduced self-awareness of cognitive and behavioral 
symptoms. Moreover, patients may have reduced awareness of motor complications 
and—in particular—of dyskinesias secondary to the levodopa treatment. The deter-
mination of dyskinesias-reduced-self-awareness (DRSA)—and of its relationship 
to functional, behavioral, and neuropsychological (dys)functions—is a key aspect 
of the debate on the gold standard for treatment in PD. Considering the above, in 
this chapter, we will discuss therapies of the advanced phase and their management 
from a neurological and neuropsychological point of view; the case of levodopa-
induced dyskinesias; the phenomenon of dyskinesias-reduced-self-awareness in 
PD; the neurocognitive approach to this phenomenon; the associated neuropsycho-
logical factor and neural underpinnings as well as from our research experience.
2.  Parkinson’s disease: therapies of the advanced phase and role of the 
neuropsychological evaluation
Along with the progressive worsening of the disease and the motor complica-
tions, the patient’s management could represent a difficult clinical challenge for 
physicians.
During the last two decades, the treatment of the PD advanced phase has 
radically changed with the advent of therapeutic options that include deep brain 
stimulation (DBS) of the subthalamic nucleus (STN) or globus pallidus internus 
(GPi), levodopa/carbidopa intestinal gel infusion (LCIG), and subcutaneous 
infusion of apomorphine [10]. These therapies demonstrated a significant and 
long-lasting improvement in the management of parkinsonian symptoms and 
motor complications but their application, in particular for DBS, needs a thorough 
evaluation of patients. In this scenario, the neuropsychological evaluation has 
acquired a leading role, due to the important implications of cognitive and affec-
tive status in the selection of the best advanced therapeutic option, and in the 
patient’s follow-up. Both STN- and GPi-DBS proved to be effective in relieving PD 
cardinal symptoms and improving patients’ quality of life. In fact, several studies 
demonstrated that DBS has a long-term efficacy in PD, yielding a 60% reduction on 
levodopa-related motor complications [11], a 40–60% improvement in quality of 
life [12], and a significant gain in quality-adjusted life years [13]. Since its break-
through in 1987, about 150,000 patients worldwide were treated with DBS, which is 
now the most common and effective surgical procedure for advanced PD. However, 
the significant improvement obtained by patients is strictly related to the selection 
of the optimal candidates. Indeed, in 1999, the scientific community developed a 
“Core Assessment Program for Surgical Interventions in PD” (CAPSIT-PD) based 
on strict neuropsychological, clinical, and surgical inclusion criteria with the aim 
of  improving the risk/benefit balance of PD patients undergoing neurosurgical 
procedures. According to the CAPSIT-PD criteria, it has been estimated that less 
than 10% of PD patients are suitable for DBS [14].
In general, the best PD surgical candidates have idiopathic Parkinson’s disease (not 
parkinsonism); tend to be younger (below age 69, but may be older); have at least 30% 
improvement at the unified Parkinson’s disease rating scale (UPDRS) part III after 
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levodopa administration; have medication-related complications, such as wearing-off 
of medications prior to the next dose, on-off fluctuations, and dyskinesias; and have 
no or mild cognitive dysfunction. The latter is one of the most controversial aspects 
of patient selection since many PD patients suffer from cognitive deficits also in the 
early phase of the disease, but are quite functional in their daily lives. Given the range 
of deleterious effects from PD-MCI/PDD and increased emphasis on neuropsychiatric 
features on patients’ management, compliance to treatment and prognosis, there is 
a compelling need for a good neuropsychological evaluation. In particular, as part of 
the cognitive and mood preoperative assessment for DBS candidacy, the CAPSIT-PD 
committee recommended the following tests: Mattis Dementia Rating Scale (MDRS) 
and Montgomery and Asberg Depression Rating Scale for general screening and mood 
evaluation; verbal fluency (letters F, A, and S), Paced Auditory Serial Addition Test 
(PASAT), Odd Man Out (OMO), and Modified Brown Peterson Paradigm (MBPP) 
for the assessment of executive functions; Rey Auditory and Verbal Learning Test 
(RAVLT) and visual amnesic battery of Signoret for the assessment of explicit mem-
ory; and short version of Tower of Hanoi for the assessment of procedural memory.
Movement disorders centers that perform DBS have adapted the CAPSIT-PD 
protocol over time to fit the needs of their individual institutions, and in 2006, 
a report from the consensus on deep brain stimulation for Parkinson’s disease, a 
project commissioned by the congress of neurological surgeons and the Movement 
Disorder Society, has been published to address all aspects of DBS preoperative 
decision-making [15].
Still, a high variability exists in the evaluation of good DBS candidates and the 
experience of the Movement Disorders Centers plays a major role in the patients’ 
selection. Especially the cognitive assessment is relevant in the candidate selection, 
since dementia is the most frequent exclusion criterion for DBS surgery. This is due 
to three relevant aspects: (1) the vast majority of PD patients show some cogni-
tive deficits, in particular, in the executive function domain; (2) dementia may 
be worsened by DBS; and (3) demented patients may not take advantage of the 
surgery-related improvement of motor symptoms. Given these premises, the clinical 
challenge is represented by the difficulty to know the extent of cognitive dysfunc-
tion that may affect the outcome of DBS. Moreover, while a thorough neuropsycho-
logical evaluation is mandatory within 1 year before DBS to exclude dementia, there 
is no consensus on the type of testing and level of performance that would exclude 
patients from receiving DBS. In 2007, the Movement Disorders Society established 
criteria for the diagnosis of PD dementia, and also proposed practical sugges-
tions for their verification [16]. Nonetheless, it is common practice to repeat the 
evaluation after 6–12 months to ascertain that cognitive functions are stable when 
borderline cognitive deficits are outlined. Moreover, it is important to ascertain that 
cognitive dysfunction is not related to treatable causes such as depression or anti-
parkinsonian medication, especially anticholinergics. Given an accurate candidate 
selection, DBS surgery showed excellent motor outcome with no or few neuropsy-
chological issues. In fact, cognitive or affective symptoms may transiently appear as 
postoperative side effects but only rarely they are permanent. In particular, only the 
verbal fluency showed a significant deterioration after DBS and exclusively in STN-
DBS-treated patients. Nonetheless, patients with preexisting mild cognitive impair-
ment (MCI) have shown a shorter latency to dementia development in comparison 
with patients with presurgical normal cognitive status [17].
Finally, in patients treated with STN-DBS, particular attention needs to be paid 
for the affective state both in the selection phase and in the postsurgical follow-up, 
since depression and anxiety may worsen in some patients and few cases of suicides 
have been reported after surgery. Therefore, current psychiatric disorders and 
moderate to severe depression are further contraindication for DBS.
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LCIG improves PD symptoms and motor complication [18] by means of a 
continuous delivery of levodopa directly in the jejunum, promoting stable plasmatic 
concentration and augmented bioavailability [19]. Unlike DBS, no strict neuropsy-
chological indications are needed for starting LCIG treatment. Nevertheless, the 
patient’s cognitive status has to be carefully evaluated. In fact, due to the gastros-
tomy and device management, the presence of severe cognitive impairment could 
unbalance the risk/benefit profile toward lower efficacy and higher prevalence of 
complications and side effects [20]. For the same reason, the presence of a caregiver 
is strongly recommended in patients with mild to moderate cognitive impairment 
undergoing LCIG treatment. On the other hand, LCIG does not seem to accelerate 
cognitive deterioration, and no significant differences in the long-term cognitive 
decline were reported in comparison with DBS or oral medical treatment [21]. 
Finally, amelioration of depression, anxiety, impulse control disorder, and psycho-
sis has also been reported [20].
Subcutaneous infusion of apomorphine is a well-established treatment for 
advanced PD [22]. Similar to LCIG, no strict neuropsychological criteria exist for 
patient’s selection, and no significant cognitive worsening seems to be associated 
with apomorphine infusion [23]. However, due to its powerful dopamine-agonist 
action, apomorphine treatment can be associated with acute confusional states, hal-
lucinations, and paranoid psychosis. On the other hand, an improvement in mood 
and anxiety has been reported.
In conclusion, the management of the advanced phase of PD still represents a 
clinical challenge. A comprehensive neuropsychological evaluation is mandatory 
to guide the physician in the correct choice of treatment and to follow-up patients 
during the progression of the disease. The neuropsychological evaluation is also 
useful for understanding any dysfunctions in terms of “awareness of symptomatol-
ogy” that may alter the compliance to the treatment and/or put the patient at risk in 
the daily living.
3. Levodopa-induced dyskinesias in Parkinson’s disease
Levodopa is the most effective drug treatment for Parkinson’s disease. However, 
its long-term use is complicated by disabling motor fluctuations and involuntary 
movements (the so-called levodopa-induced dyskinesias, LIDs) [24]. LIDs are 
involuntary choreiform (“soft”) movements, which disturb the execution of volun-
tary movements and, when they are serious, cause very important disabilities in the 
patient. Dyskinesias are due to a denervation hypersensitivity of striatal neurons: 
changes in levodopa blood levels (dopamine precursor, with very short drug half-
life) trigger dyskinesias because striatal cells—which have not received dopamine 
from the substantia nigra for long—become hypersensitive to the molecule. Despite 
significant advances, the pathogenesis of LIDs remains incompletely understood. 
It is known that dyskinesias appear only after dopaminergic therapy and there is a 
time lag between the start of treatment and the emergence of LIDs. Several possible 
mechanisms, both peripheral and central, have been proposed. A schematic repre-
sentation of the whole process leading to LID is proposed in Figure 1.
LIDs are clinically heterogeneous [25]. LIDs generally first appear on the side 
worst affected by Parkinson’s disease and in legs before arms [25]. Based on their 
relationship with levodopa dosing, LIDs are classified as peak-dose, end of dose, 
diphasic, off-state, on-state, and yo-yo dyskinesias (see Table 1). Peak-dose dyski-
nesias are the consequence of the maximum levodopa concentration (linked to an 
increase in dopamine at the synaptic level); diphasic dyskinesias are present both in 
growth and in decrease of the dopamine level; and end of dose dyskinesias are due 
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to a reduction of dopamine at the synaptic level. In this last case (or in the case of 
dystonia), we are in the presence of protracted movements that cause the patient to 
twist the neck, arms, legs, and hands (alterations of the harmonic regulation of the 
muscular tone between the agonist-antagonist muscle groups). They usually occur 
when the levodopa levels in the blood are low/reduced rapidly, more frequently at 
night or in the morning, before the first dose of levodopa (see Figure 2).
Figure 1. 
Schematization of the pathophysiological processes leading to the emergence of dyskinesias.
Figure 2. 
Main types of dyskinesias in relation to the plasma concentration of levodopa over time.
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Once levodopa-induced dyskinesias have developed in patients, they are dif-
ficult to treat [24]. LIDs negatively affect patients’ quality of life and substantially 
augment the costs associated with their health care [26]. Prevention of onset would 
therefore be the best strategy [25]. Recommended interventions include: controlled-
release preparations of levodopa; continuous delivery of levodopa; using catechol-
O-methyl transferase (COMT) inhibitors; using dopamine receptor agonists; and 
neuroprotective agents [25]. In the case of overt LIDs, some treatment options may 
include: reduction of levodopa doses; using dopamine receptor agonists; drugs 
acting on NMDA receptors; drugs acting on serotonergic systems; miscellaneous 
agents; and neurosurgery [25].
LIDs are certainly one of the most common disabling motor complications in 
advanced PD. Indeed, the subjective ability to perceive motor impairment is a clini-
cal phenomenon that needs to be adequately analyzed. Reduced awareness of illness 
is one of the factors associated with medication nonadherence. Moreover, unaware 
parkinsonian patients are of particular concern to caregivers, as they may incur 
unnecessary risks in order to complete their daily activities, causing a deterioration 
of their own and others’ quality of life [27].
4. Dyskinesias-reduced-self-awareness (DRSA) in Parkinson’s disease
In clinical neuropsychology, “awareness of illness” is considered as a form of 
self-knowledge (the so-called “self-awareness”). Its construct is complex when 
considering an operational semantic level [28]. This term is used to describe the 
ability to identify, recognize, and evaluate a deficit in sensory, perceptual, motor, 
affective, or cognitive functioning and to consider the impact of these disturbances 
on the patient’s daily life [8, 29–34].
Reduced self-awareness leads to numerous negative effects, such as augmented 
stress and burden for primary caregivers, families, personal care and health care 
partner. Moreover, it worsens patient-caregiver relations, eases deflection of mood, 
somatoform anxiety, and poor adherence to treatment [35]. Moreover, a reduction 
in self-awareness has been found to be associated with a decline in help-seeking 
behavior and compliance with medical treatment, presumably because of a reduc-
tion in motivation [34].
The neurocognitive approach considers cognitive functions and behavior as 
closely linked to the function of single brain area, neural pathways, or cortical 
networks. This approach emphasizes how reduced self-awareness is associated 
to brain pathology, particularly concerning focal lesions, motivational and 
emotional factors, and concomitant cognitive disturbances [8, 29–33, 36]. In 
particular, since the frontal lobes are involved in self-awareness and monitoring 
of cognitive functions, reduced self-awareness could be viewed as a deficit in self-
monitoring [37]. Furthermore, deficits in the internal representation of external 
outputs have been suggested to be a possible mechanism of decreased awareness 
[32, 34, 38]. Indeed, any deficit in monitoring, response inhibition, or cognitive 
flexibility can affect patients’ self-awareness [34, 35]. In our experience, patients 
with neurodegenerative disorders such as Alzheimer’s and Parkinson’s (PD) 
diseases or frontotemporal dementia show reduced self-awareness due to deficits 
in self-monitoring [8, 9, 29–31, 39, 49].
When considering PD, it may result in reduced self-awareness of cognitive and 
behavioral symptoms. A form of awareness reduction for dysexecutive [40–42] 
and mnestic [43, 44] symptoms has been previously detected. If we consider the 
diagnostic spectrum ranging from complete cognition, to mild cognitive impair-
ment (MCI), to the major neurocognitive disorder, a reduced self-awareness is 
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associated with the level of cognitive impairment and the simultaneous presence of 
mood abnormalities or executive dysfunctions [45]. In particular, reduced self-
awareness has been detected in 36% of PD patients with mild dementia and 16% 
with MCI [45]. Moreover, more severe unawareness for cognitive impairment has 
been associated to depression, reduced hedonic tone, and more severe executive 
dysfunctions [45].
The phenomenon also manifests itself on the motor side. The determination of 
dyskinesias-reduced-self-awareness (DRSA)—and of its relationship to functional, 
behavioral, and neuropsychological (dys)functions—is a key aspect of the debate 
on the gold standard for treatment in PD. However, the relationship between 
subjective and objective evaluations of motor symptomatology in PD has so far 
been poorly investigated. Previous evidence has shown that parkinsonian patients 
have deficits in the subjective evaluation of levodopa-induced dyskinesias, with 
percentages ranging from 23 to 61% [39, 46–49]. Importantly, the hypothesis that 
dopaminergic overstimulation of mesocorticolimbic loops might be responsible for 
DRSA is currently suggested [8, 9, 39]; however, the role of dopaminergic treatment 
in the occurrence of metacognitive-executive dysfunctions is not yet fully clarified 
and requires more attention from the scientific community. Importantly, the kind 
of association between DRSA and executive dysfunction in PD patients has not 
been solved yet [8, 9, 49].
5.  The proposal of a neurocognitive model of DRSA in Parkinson’s 
disease
Reduced self-awareness may be considered an organically based decreased/lack 
of insight about neurological, cognitive, and behavioral deficits [34]. After a brain 
damage, sometimes patients become unable to detect the presence—or to realisti-
cally assess the severity—of sensory deficits, and motor, affective, or cognitive 
impairments, although, they are evident to doctors and family [34].
“Self-awareness” is a complex neuropsychological notion, defined as “the 
ability to consciously process information about ourselves in a manner that 
reflects a relatively objective view while maintaining our unique phenomeno-
logical or subjective sense of self ” ([50], p. 301). Indeed, self-awareness is above 
all a form of self-knowledge and a higher-order cognitive function covering 
information about the state of the disease, its functional consequences, the 
way in which it affects the patient and influences his/her interaction with the 
environment [34].
A neurocognitive model of awareness may help in understanding the contri-
bution of metacognitive-executive abilities related to DRSA in PD [8, 9, 34, 49]. 
Indeed, it is possible to interpret a reduction in disease awareness by referring to 
the Cognitive Awareness Model (CAM), which incorporates a comparator system 
within the central executive to detect mismatches between a personal database and 
experience of failures and successes [51]. When a discrepancy is found, a signal is 
sent out to the metacognitive awareness system, enabling a conscious experience 
of failure/success. If the executive system does not work properly, the comparator 
mechanism may not detect mismatches, and subsequently experienced failures may 
not produce any metacognitive output or conscious awareness, leading to an “execu-
tive unawareness” in the CAM [51]. In line with the interpretative model associating 
DRSA with executive dysfunction [8, 9, 34, 49], if the comparator mechanism for 
“attentive performance-monitoring” is compromised, then PD patients lose the 
ability to recognize their motor disturbances and levodopa-induced dyskinesias do 
not achieve conscious awareness.
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6. Neuropsychological factors associated with DRSA
In their first study, Amanzio et al. [39] evaluated the presence of awareness of 
movement disorders in 25 PD patients. None before have analyzed the differences in 
DRSA by comparing the “on” and “off” states. PD patients were compared on three 
different scales to measure awareness of movement disorders: global awareness 
of movement (GAM) disorders, dyskinesia/hypo-bradykinesia rating scales. The 
authors found that PD patients had greater awareness and psychological suffering 
in the “off” than in the “on” state: patients explicitly complained about hypokine-
sias, mood-related symptoms, and perceived disability in their daily living [39]. 
Importantly, patients only showed DRSA in the “on” state and this reduced aware-
ness was associated with executive cognitive dysfunction [39].
Since the dopaminergic overstimulation of mesocorticolimbic pathways may 
cause a dysfunction of prefrontal-subcortical connections and, subsequently, may 
negatively affect executive functions, more attention has been given to metacogni-
tive-executive abilities related to action monitoring, that represent a novel explana-
tion of DRSA [49]. The Wisconsin Card Sorting Test-metacognitive-version [52] 
turned out to be a fruitful neuropsychological tool to assess the executive functions 
of the prefrontal-ventral-striatal circuitry [49]. Indeed, DRSA was associated with 
global monitoring, monitoring resolution, and control sensitivity, suggesting that 
when the comparator mechanism for monitoring attentive performance is compro-
mised at a prefrontal striatal level, patients lose the ability to recognize dyskinesias 
and to be aware of nonvoluntary movements [49]. These results support the inter-
pretive efficacy of the CAM model not only in the case of major neurocognitive 
disorders [29–31], acquired brain injuries [33], and neuropsychiatric disorders [33], 
but also in the case of movement disorders.
Although dyskinesias-reduced-self-awareness in PD is related to deficit in 
metacognition, other factors, such as “Theory of Mind” (ToM), could operate [8].  
Indeed, ToM has been a topic of interest in recent studies on unawareness of disease 
in neuropsychiatric disorders such as schizophrenia and bipolar disorder [33]. 
Not only decreased self-awareness may be considered a critical manifestation of 
impaired ToM abilities—in terms of meta-representation—but second-order false 
belief tasks and affective ToM abilities [33] seem to be of critical importance for 
preserved awareness of illness. For all the above, Palermo and collaborators [8] 
investigated whether DRSA could be influenced by cognitive and affective ToM as 
a contributing factor that has not yet been evaluated. Perspective-taking abilities 
were tested using ToM visual stories [53], while the ability to recognize the mental 
state of others was tested using the Reading the Mind in the Eyes task [54]. Multiple 
logistic regression models were used to estimate the impact of ToM disabilities on 
awareness evaluation [8]. DRSA was associated with the automatic and rapid pro-
cesses of decoding mental states [8], which have often been ascribed to the affective 
ToM subcomponent [54]. Moreover, the association with executive dysfunctions 
has been reconfirmed [8].
7.  New findings concerning the association between executive functions 
and the neural correlates of DRSA
We have previously demonstrated a noteworthy association between DRSA and 
decreased functional recruitment of the cingulo-frontal and cingulo-opercular 
pathways due to prolonged iatrogenic overstimulation [8, 39, 49]. This kind of 
association engaged in loading executive-monitoring onto the processing of task-
relevant information, so as to avoid interference by goal-irrelevant stimuli.
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Importantly, response-inhibition dysfunction is often observed in PD. Besides 
being involved in response-inhibition tasks, the anterior cingulate cortex is part of 
a functional system based on self-awareness and engaged across cognitive, affec-
tive, and behavioral contexts [9]. Considering the above—and since a dysfunction 
in action monitoring related to the cingulo-frontal-ventral striatal circuit would be 
associated with DRSA—it is important to evaluate whether and how ACC could be 
involved in the arising of DRSA in PD.
The association between blood oxygenation level-dependent response over the 
whole brain during an ACC-sensitive response-inhibition task and DRSA was inves-
tigated to clarify the kind of association between brain dysfunction and concomitant 
cognitive-behavioral disturbances [9]. The proposed paradigm is a prototypical 
task to measure the ability to inhibit an overpowering response [55, 56]. The task 
involves visual discrimination and a simple choice: to respond (GO) or not respond 
(NoGO) depending on the current stimulus. Response conflict arises from com-
petition between the execution and the inhibition of a single response (response-
inhibition conflict), rather than from competition between two alternative responses 
(response-selection conflict) [55, 56].
DRSA was associated with a reduced functional recruitment in the bilateral 
ACC, bilateral anterior insular cortex, and right dorsolateral prefrontal cortex 
(p < 0.05) (see Table 2 and Figure 3). Moreover, DS-I scores significantly corre-
lated with percent errors on the NoGO condition (r = 0.491, p = 0.009). Indeed, the 
worse the response-inhibition’s performance, the worse the ability of a subject to 
notice and adequately assess the severity of his/her own dyskinesias [9].
Brain areas MNI coordinates Voxels r-Score p-Value
X Y Z
ACC 4 26 29 982 −0.84 0.000
ACC −5 25 27 798 −0.81 0.000
AIC 33 22 −4 1855 −0.64 0.001
AIC −39 27 3 1654 −0.41 0.002
DLPFC −45 10 47 2128 −0.39 0.007
Peak activity coordinates are given in MNI space. Peak activities are significant at p < 0.05, FWE corrected for multiple 
comparisons at the voxel level. ACC: anterior cingulate cortex; AIC: anterior insular cortex; DLPFC: dorsolateral 
prefrontal cortex.
Table 2. 
Linear correlation between the “NoGO” vs. “GO” contrast and DS-I scores (FWE p < 0.05).
Figure 3. 
Brain area negatively associated with DRSA in the NoGO/GO contrast (adapted from [9]).
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8. Conclusions
Our findings show how DRSA was related with metacognitive-executive func-
tions and the affective component of ToM, thus caused by a complex interplay 
between specific neuropsychological and motor factors.
Executive functions are a predictor of DRSA pathogenesis, with a key role played 
by ACC. Imaging biomarkers for DRSA are important to be studied, especially when 
the neuropsychological assessment seems to be normal. Our findings suggest that 
when the comparator mechanism for monitoring attentive performance is compro-
mised at a prefrontal striatal level, patients lose the ability to recognize their motor 
disturbances that do not achieve conscious awareness.
It is important to consider the specific neuropsychological characteristics 
(including DRSA and metacognitive-executive (dys)functions) along with the 
neurological symptoms to define tailored interventions and adopt a personalized 
clinical approach avoiding increased doses of dopaminergic drugs, which would in 
turn enhance the risk of side effects.
Acknowledgements
We would like to thank all the members of the Center for the Study of the 
Movement’s Disorder, directed by Professor Leonardo Lopiano (Department 
of Neuroscience, University of Turin, Italy). In particular, special thanks go to 
Professor Lopiano for his teachings, valuable scientific supervision, and expert 
guidance and Dr. Elisa Montanaro, Dr. Maurizio Zibetti, and Dr. Mario Rizzone for 
their precious support in every phase of the research.
Finally, we would like to thank Dr. Maria Consuelo Valentini, director of the 
Neuroradiology Unit (Azienda Ospedaliera Universitaria “Città della Salute e 
della Scienza di Torino”) for her teachings, precious collaboration, and scientific 
supervision.
The authors have not received any funding from any institution, including per-
sonal relationships, interests, grants, employment, affiliations, patents, inventions, 
honoraria, consultancies, royalties, stock options/ownership, or expert testimony 
for the last 12 months.
Conflict of interest
No conflicts of interest considering all the authors.
Parkinson’s Disease and Beyond - A Neurocognitive Approach
12
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Author details
Sara Palermo1*, Rosalba Morese2, Carlo Alberto Artusi3, Mario Stanziano4  
and Alberto Romagnolo3
1 Department of Psychology, University of Turin, Turin, Italy
2 Department of Psychology, Center for Cognitive Science, University of Turin, 
Turin, Italy
3 Department of Neuroscience “Rita Levi Montalcini”, University of Turin,  
Turin, Italy
4 Department of Diagnostic Imaging and Radiotherapy, Radiology Institute, 
University of Turin, Azienda Ospedaliera Universitaria “Città della Salute e della 
Scienza di Torino”, Turin, Italy
*Address all correspondence to: sara.palermo@unito.it
13
Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease…
DOI: http://dx.doi.org/10.5772/intechopen.86384
[1] Tian YY, Tang CJ, Wu J, Zhou 
JS. Parkinson’s disease in China. 
Neurological Sciences. 2011;32(1):23-30
[2] Litvan I, Aarsland D, Adler 
CH, Goldman JG, Kulisevsky J, 
Mollenhauer B, et al. MDS task force 
on mild cognitive impairment in 
Parkinson’s disease: Critical review 
of PD-MCI. Movement Disorders. 
2011;26(10):1814-1824
[3] Ceravolo R, Pagni C, Tognoni G, 
Bonuccelli U. The epidemiology and 
clinical manifestations of dysexecutive 
syndrome in Parkinson’s disease. 
Frontiers in Neurology. 2012;3:159
[4] Kehagia A, Barker R, Robbins T.  
Neuropsychological and clinical 
heterogeneity of cognitive impairment 
and dementia in patients with 
Parkinson’s disease. Lancet Neurology. 
2010;9(12):1200-1213
[5] Janvin CC, Larsen JP, Aarsland D, 
Hugdahl K. Subtypes of mild cognitive 
impairment in Parkinson’s disease: 
Progression to dementia. Movement 
Disorders. 2006;21(9):1343-1349
[6] Hanagasi HA, Tufekcioglu Z, Emre 
M. Dementia in Parkinson’s disease. 
Journal of the Neurological Sciences. 
2017;374:26-31
[7] Hoogland J, Boel JA, de Bie 
RMA, Schmand BA, Geskus RB, 
Dalrymple-Alford JC, et al. MDS study 
group “validation of mild cognitive 
impairment in Parkinson disease”. Risk 
of Parkinson’s disease dementia related 
to level I MDS PD-MCI. Movement 
Disorders. 2019;34(3):430-435
[8] Palermo S, Lopiano L, Zibetti M, 
Rosato R, Leotta D, Amanzio M. A novel 
framework for understanding reduced 
awareness of dyskinesias in Parkinson’s 
disease. Parkinsonism & Related 
Disorders. 2017;39:58-63
[9] Palermo S, Lopiano L, Morese R, 
et al. Role of the cingulate cortex in 
dyskinesias-reduced-self-awareness: 
An fMRI study on Parkinson’s disease 
patients. Frontiers in Psychology. 
2018;9:1765
[10] Antonini A, Moro E, Godeiro C, 
Reichmann H. Medical and surgical 
management of advanced Parkinson’s 
disease. Movement Disorders. 
2018;33(6):900-908
[11] Rizzone MG, Fasano A, Daniele 
A, Zibetti M, Merola A, Rizzi L, et al. 
Long-term outcome of subthalamic 
nucleus DBS in Parkinson’s disease: 
From the advanced phase towards 
the late stage of the disease? 
Parkinsonism & Related Disorders. 
2014;20(4):376-381
[12] Dafsari HS, Reker P, Stalinski 
L, Silverdale M, Rizos A, Ashkan 
K, et al. EUROPAR and the IPMDS 
(international Parkinson’s and 
movement disorders society) non-motor 
Parkinson’s disease study group. Quality 
of life outcome after subthalamic 
stimulation in Parkinson’s disease 
depends on age. Movement Disorders. 
2018;33(1):99-107
[13] Espay AJ, Vaughan JE, Marras C, 
Fowler R, Eckman MH. Early versus 
delayed bilateral subthalamic deep brain 
stimulation for Parkinson’s disease: A 
decision analysis. Movement Disorders. 
2010;25(10):1456-1463
[14] Kestenbaum M, Ford B, Louis 
ED. Estimating the proportion of 
essential tremor and Parkinson’s 
disease patients undergoing deep brain 
stimulation surgery: Five-year data from 
Columbia University medical center 
(2009-2014). Movement Disorders 
Clinical Practice. 2015;2:384-387
[15] Lang AE, Houeto JL, Krack P, 
Kubu C, Lyons KE, Moro E, et al. Deep 
References
14
Parkinson’s Disease and Beyond - A Neurocognitive Approach
brain stimulation: Preoperative issues. 
Movement Disorders. 2006;21 
(Suppl 14):S171-S196
[16] Emre M, Aarsland D, Brown R, 
Burn DJ, Duyckaerts C, Mizuno Y, 
et al. Clinical diagnostic criteria for 
dementia associated with Parkinson’s 
disease. Movement Disorders. 
2007;22(12):1689-1707
[17] Merola A, Rizzi L, Artusi CA, et al. 
Subthalamic deep brain stimulation: 
Clinical and neuropsychological 
outcomes in mild cognitive impaired 
parkinsonian patients. Journal of 
Neurology. 2014;261(9):1745-1751
[18] Olanow CW, Kieburtz K, Odin P, 
et al. Continuous intrajejunal infusion 
of levodopa-carbidopa intestinal gel 
for patients with advanced Parkinson’s 
disease: A randomised, controlled, 
double-blind, double-dummy study. 
Lancet Neurology. 2014;13(2):141-149
[19] Nyholm D, Odin P, Johansson 
A, Chatamra K, Locke C, Dutta S, 
et al. Pharmacokinetics of levodopa, 
carbidopa, and 3-O-methyldopa 
following 16-hour jejunal infusion of 
levodopa-carbidopa intestinal gel in 
advanced Parkinson’s disease patients. 
The AAPS Journal. 2013;15(2):316-323
[20] Catalán MJ, Antonini A, Calopa 
M, et al. Can suitable candidates 
for levodopa/carbidopa intestinal 
gel therapy be identified using 
current evidence? eNeurologicalSci. 
2017;8:44-53
[21] Merola A, Espay AJ, Romagnolo A, 
Bernardini A, Rizzi L, Rosso M, et al. 
Advanced therapies in Parkinson’s 
disease: Long-term retrospective study. 
Parkinsonism & Related Disorders. 
2016;29:104-108
[22] Katzenschlager R, Poewe W, Rascol 
O, et al. Apomorphine subcutaneous 
infusion in patients with Parkinson’s 
disease with persistent motor 
fluctuations (TOLEDO): A multicentre, 
double-blind, randomised, placebo-
controlled trial. Lancet Neurology. 
2018;17(9):749-759
[23] Volkmann J, Albanese A, 
Antonini A, et al. Selecting deep brain 
stimulation or infusion therapies in 
advanced Parkinson’s disease: An 
evidence-based review. Journal of 
Neurology. 2013;260(11):2701-2714
[24] Calabresi P, Di Filippo M, Ghiglieri 
V, Tambasco N, Picconi B. Levodopa-
induced dyskinesias in patients with 
Parkinson’s disease: Filling the bench-
to-bedside gap. Lancet Neurology. 
2010;9(11):1106-1117
[25] Thanvi B, Lo N. Robinson. 
Levodopa-induced dyskinesia in 
Parkinson’s disease: Clinical features, 
pathogenesis, prevention and treatment. 
Postgraduate Medical Journal. 
2007;83(980):384-388
[26] Dodel RC, Berger K, Oertel 
WH. Health-related quality of 
life and healthcare utilisation in 
patients with Parkinson’s disease: 
Impact of motor fluctuations and 
dyskinesias. PharmacoEconomics. 
2001;19:1013-1038
[27] Jenkinson PM, Edelstyn NM, 
Stephens R, Ellis SJ. Why are 
some Parkinson disease patients 
unaware of their dyskinesias? 
Cognitive and Behavioral Neurology. 
2009;22(2):117-121
[28] Bach LJ, Davis AS. Self-awareness 
after acquired and traumatic 
brain injury. Neuropsychological 
Rehabilitation. 2006;16:397-414
[29] Amanzio M, Torta DM, Sacco 
K, Cauda F, D’Agata F, Duca S, et al. 
Unawareness of deficits in Alzheimer’s 
disease: Role of the cingulate cortex. 
Brain. 2011;134(Pt 4):1061-1076
15
Levodopa-Induced Dyskinesias and Dyskinesias-Reduced-Self-Awareness in Parkinson’s Disease…
DOI: http://dx.doi.org/10.5772/intechopen.86384
[30] Amanzio M, Vase L, Leotta D, 
Miceli R, Palermo S, Geminiani G.  
Impaired awareness of deficits in 
Alzheimer’s disease: The role of 
everyday executive dysfunction. Journal 
of the International Neuropsychological 
Society. 2013;19(1):63-72
[31] Amanzio M, D’Agata F, Palermo 
S, Rubino E, Zucca M, Galati A, 
et al. Neural correlates of reduced 
awareness in instrumental activities 
of daily living in frontotemporal 
dementia. Experimental Gerontology. 
2016;83:158-164
[32] Palermo S, Leotta D, Bongioanni 
MR, Amanzio M. Unawareness of 
deficits in ischemic injury: Role of 
the cingulate cortex. Neurocase. 
2014;20(5):540-555
[33] Palermo S, Cauda F, Costa T, 
Duca S, Gallino G, Geminiani G, et al. 
Unawareness of bipolar disorder: The 
role of the cingulate cortex. Neurocase. 
2015;21(4):438-447
[34] Palermo S. Chapter 3: Reduced 
self-awareness across pathologies: 
Involvement of the anterior cingulate 
cortex. In: Horizons in Neuroscience 
Research. Vol. 28. Hauppauge, NY: Nova 
Science Publishers; 2017
[35] O’Keeffe FM, Murray B, Coen RF, 
Dockree PM, Bellgrove MA, Garavan H, 
et al. Loss of insight in frontotemporal 
dementia, corticobasal degeneration 
and progressive supranuclear palsy. 
Brain. 2007;130(Pt 3):753-764
[36] McGlynn SM, Schacter 
DL. Unawareness of deficits in 
neuropsychological syndromes. 
Journal of Clinical and Experimental 
Neuropsychology. 1989;11(2):143-205
[37] Stuss DT, Benson DF.  
Neuropsychological studies of the 
frontal lobes. Psychological Bulletin. 
1984;95:3-28
[38] Goldberg E, Barr WB. Three 
possible mechanisms of unawareness of 
deficit. In: Prigatano GP, Schacter DL, 
editors. Awareness of Deficit After Brain 
Injury. New York: Oxford University 
Press Inc; 1991. pp. 152-175
[39] Amanzio M, Monteverdi S, 
Giordano A, Soliveri P, Filippi P, 
Geminiani G. Impaired awareness of 
movement disorders in Parkinson’s 
disease. Brain and Cognition. 
2010;72(3):337-346
[40] Kudlicka A, Clare L, Hindle 
JV. Executive functions in Parkinson’s 
disease: Systematic review and 
meta-analysis. Movement Disorders. 
2011;26(13):2305-2315
[41] Kudlicka A, Clare L, Hindle 
JV. Awareness of executive deficits in 
people with Parkinson’s disease. Journal 
of the International Neuropsychological 
Society. 2013;19(05):559-570
[42] Sitek EJ, Sołtan W, Wieczorek D, 
Schinwelski M, Robowski P, Harciarek 
M, et al. Self-awareness of executive 
dysfunction in Huntington’s disease: 
Comparison with Parkinson’s disease 
and cervical dystonia. Psychiatry 
and Clinical Neurosciences. 
2013;67(1):59-62
[43] Lautenschlager NT. Awareness of 
memory deficits in subjective cognitive 
decline, mild cognitive impairment, 
Alzheimer’s disease and Parkinson’s 
disease. International Psychogeriatrics. 
2015;27(3):355-356
[44] Lehrner J, Kogler S, Lamm C, Moser 
D, Klug S, Pusswald G, et al. Awareness 
of memory deficits in subjective 
cognitive decline, mild cognitive 
impairment, Alzheimer’s disease and 
Parkinson’s disease. International 
Psychogeriatrics. 2015;27(3):357-366
[45] Orfei MD, Assogna F, Pellicano C, 
Pontieri FE, Caltagirone C,  
Parkinson’s Disease and Beyond - A Neurocognitive Approach
16
Pierantozzi M, et al. Anosognosia for 
cognitive and behavioral symptoms in 
Parkinson’s disease with mild dementia 
and mild cognitive impairment: 
Frequency and neuropsychological/
neuropsychiatric correlates. 
Parkinsonism & Related Disorders. 
2018;54:62-67
[46] Maier F, Prigatano GP, Kalbe E,  
Barbe MT, Eggers C, Lewis CJ, et al. 
Impaired self-awareness of motor 
deficits in Parkinson’s disease: 
Association with motor asymmetry 
and motor phenotypes. Movement 
Disorders. 2012;27(11):1443-1447
[47] Pietracupa S, Fasano A, Fabbrini 
G, Sarchioto M, Bloise M, Latorre A, 
et al. Poor self-awareness of levodopa-
induced dyskinesias in Parkinson’s 
disease: Clinical features and 
mechanisms. Parkinsonism & Related 
Disorders. 2013;19(11):1004-1008
[48] Sitek EJ, Soltan W, Wieczorek 
D, Robowski P, Schinwelski M, 
Slawek J. Assessing self-awareness 
of dyskinesias in Parkinson’s disease 
through movie materials. Functional 
Neurology. 2011;26(3):121-126
[49] Amanzio M, Palermo S, Zucca M, 
Rosato R, Rubino E, Leotta D, et al. 
Neuropsychological correlates of 
pre-frailty in neurocognitive disorders: 
A possible role for metacognitive 
dysfunction and mood changes. 
Frontiers in Medicine. 2017;15(4):199
[50] Prigatano GP. The problem 
of impaired self-awareness in 
neuropsychological rehabilitation. 
In: Leon-Carrion J, editor. 
Neuropsychological Rehabilitation 
Fundamentals, Innovations, and 
Directions. Florida: GR/St Lucie Press; 
1997. pp. 301-312
[51] Agnew S, Morris R. The 
heterogeneity of anosognosia for 
memory impairment in Alzheimer’s 
disease: A review of the literature and 
a proposed model. Aging and Mental 
Health. 1998;2:9-15
[52] Koren D, Seidman LJ, Goldsmith 
M, Harvey PD. Real-world cognitive-
and metacognitive-dysfunction in 
schizophrenia: A new approach for 
measuring (and remediating) more 
“right stuff”. Schizophrenia Bulletin. 
2006;32(2):310-326
[53] Amanzio M, Geminiani G, Leotta 
D, Cappa S. Metaphor comprehension 
in Alzheimer’s disease: Novelty matters. 
Brain and Language. 2008;107(1):1-10
[54] Baron-Cohen S, Wheelwright S, 
Hill J, Raste Y, Plumb I. The “reading 
the mind in the eyes” test revised 
version: A study with normal adults, 
and adults with Asperger syndrome 
or high-functioning autism. Journal 
of Child Psychology and Psychiatry. 
2001;42:241-251
[55] Braver TS, Barch DM, Gray JR, 
Molfese DL, Snyder A. Anterior 
cingulate cortex and response conflict: 
Effects of frequency, inhibition and 
errors. Cerebral Cortex. 2001;11:825-836
[56] Palermo S, Stanziano M, Morese 
R. Commentary: Anterior cingulate 
cortex and response conflict: Effects 
of frequency, inhibition and errors. 
Frontiers in Behavioral Neuroscience. 
2018;12:171
